ch.oddb.org
 
Apotheken | Doctor | Drugs | Hospital | Interactions | MiGeL | Registration owner | Services
Information for professionals for Meladinine®:Galderma SA
Complete information for professionalsDDDPrint 
Galenic Form / Therapeutic GroupComposition.EffectsPharm.kinetikIndication.UsageRestrictions.Unwanted effects
Interactions.OverdoseOther adviceSwissmedic-Nr.Last update of information 
D05BA02 - MethoxsalenATC-DDD Version 2016. Source: WHO
D - Dermatologicals

Most of the drugs in this group are preparations for topical use. Some few preparations for systemic use with clear dermatological applications, e.g. griseofulvin (antimycotic), retinoids (for treatment of acne) and psoralens and retinoids (for treatment of psoriasis) are classified in this group.

Only oral and parenteral preparations in ATC group D are given DDDs. Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease. Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.

D05 - Antipsoriatics
 
D05B - Antipsoriatics for Systemic Use

This group comprises drugs for systemic use against psoriasis. Antineoplastic agents, sometimes used in severe psoriasis, are classified in group L - Antineoplastic and immunomodulating agents.
Agents with immunosuppressant properties indicated for treatment of psoriasis are classified in L04 - Immunosuppressants.

D05BA - Psoralens for Systemic Use

Methoxsalen used in extracorporeal photopheresis systems is also classified here.

The DDDs for psoralens for systemic use are based on the combined treatment with drug and UV-A irradiation.

D05BA02 - Methoxsalen
DoseRoute of administrationNote
 O 
2025 ©ywesee GmbH
Settings | Help | Login | Contact | Home